Benzinga··Vandana SinghTenaya Therapeutics Surges 31% on Alnylam Cardiovascular Research Deal
Tenaya Therapeutics surges 31% after partnering with Alnylam on cardiovascular genetic targets, securing $10M upfront and $1.13B in potential milestone payments.
TNYAALNYgene therapycardiovascular disease